氟胸腺嘧啶PET在6周预测帕博利珠单抗治疗的黑色素瘤患者12周CT评估的疗效
单中心先导研究纳入5例不可切除IV期黑色素瘤患者,比较6周氟胸腺嘧啶PET/CT与12周CT评估帕博利珠单抗疗效的一致性。6周FLT-PET/CT与12周CT评估一致性kappa=0.615(P=0.025),5例中3例CT评估为应答者;应答者基线增殖肿瘤体积均值较低、骨髓与肝脏SUVmax比值较高,6周时肿瘤体积和肿瘤增殖下降。作者认为FLT-PET/CT有潜力作为抗PD1免疫治疗早期疗效预测手段,需更大规模研究证实。
要点
- 6周FLT-PET/CT与12周CT评估疗效一致性kappa=0.615(P=0.025)。
- 5例中3例按免疫相关疗效评价标准在CT上判为应答者。
- 应答者基线增殖肿瘤体积均值较低、骨髓与肝脏SUVmax比值较高。
核心结论
- 本研究显示FLT-PET/CT有潜力作为转移性黑色素瘤患者接受抗PD1免疫治疗的早期疗效预测手段,需更大规模研究证实。
研究设计与样本
- 单中心先导研究纳入5例不可切除IV期黑色素瘤患者,基线和6周行FLT-PET/CT,基线和12周行CT。
- FLT-PET/CT疗效按PET实体瘤疗效评价标准评估,CT疗效按免疫相关疗效评价标准评估,患者分为应答者(完全缓解、部分缓解)和非应答者(疾病稳定、疾病进展)。
- 提取8项基线FLT-PET/CT参数和8项6周变化参数(相对基线的百分比变化)。
主要发现
- 6周FLT-PET/CT与12周CT评估一致性kappa=0.615,P=0.025。
- 5例中3例按免疫相关疗效评价标准在CT上判为应答者。
- 基线时应答者增殖肿瘤体积均值较低、骨髓与肝脏SUVmax比值较高。
- 6周时应答者肿瘤体积和肿瘤增殖下降。
关键数值与推荐
- FLT-PET/CT疗效评估采用PET实体瘤疗效评价标准,CT疗效评估采用免疫相关疗效评价标准。
- 一致性采用Cohen kappa计算,结果为kappa=0.615,P=0.025。
- 基线提取8项参数:SUVmax、SUVpeak、SUVSD、SUVmean、增殖肿瘤体积、总病灶增殖、骨髓与肝脏SUVmax比值、脾与肝脏SUVmax比值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 本研究为单中心先导研究,样本量为5例。
- 作者指出需更大规模研究证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Investigate the ability of F-fluorothymidine (FLT) PET combined with CT at 6 weeks to predict treatment response at 12 weeks after treatment with pembrolizumab. METHODS: Five patients with unresectable stage IV melanoma were included in this single-institution pilot study. Patients underwent FLT-PET/CT (baseline and 6 weeks) and CT (baseline and 12 weeks). FLT-PET/CT response and CT response were assessed using PET Response Criteria in Solid Tumors and immune Response Evaluation Criteria in Solid Tumors, respectively. Patients were categorized as responders (complete response, partial response) and nonresponders (stable disease, progressive disease). Agreement between 6-week FLT-PET/CT and 12-week CT was calculated using Cohen kappa's agreement. Eight baseline FLT-PET/CT parameters were extracted: SUVmax, SUVpeak, SUVSD, SUVmean, proliferative tumor volume, total lesion proliferation, bone marrow-to-liver SUVmax ratio, and spleen-to-liver SUVmax ratio. Eight delta-parameters were extracted at 6 weeks by calculating variation in FLT uptake as percentage change from baseline. RESULTS: Agreement between 6-week FLT-PET/CT and 12-week CT was kappa = 0.615, P = 0.025. Three of 5 patients were categorized as responders on CT by immune Response Evaluation Criteria in Solid Tumors. At baseline, responders had a lower mean proliferative tumor volume and a higher bone marrow-to-liver SUVmax ratio. At 6 weeks, responders demonstrated a decrease in tumor volume and tumor proliferation. CONCLUSIONS: Our study illustrates the potential for FLT-PET/CT as an early predictor of response for patients with metastatic melanoma on anti-PD1 immunotherapy. Larger studies are indicated to confirm these findings.
引用
- Yeh R, Trager MH, Rizk EM, et al. FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. Clin Nucl Med. 2020. PMID: 32108700. doi:10.1097/RLU.0000000000002967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。